ARCHIVING REGULATIONS

Similar documents
Regulatory Binder: Set-up and Maintenance

Guidance for Industry - Computerized Systems Used in Clinical Trials

DATA INTEGRITY IN CLINICAL RESEARCH. Singapore Clinical Research Professional (CRP) Forum 25 August 2017

FRAMEWORK OF CHARACTERISTICS OF A QUALIFIED SITE TEAM: How Does Yours Measure Up?

Objectives Discuss the importance of proper data collection. Identify the types of data collected for clinical trials. List potential source documents

Multi-Site Coordination Process. Drafted by: Ester Dimayuga Page 1 of 18

NEUROENDOVASCULAR TRIALS

The European Medicines Agency Inspections ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA:

I. Purpose. II. Definitions. Last Approval Date

ROLE OF THE RESEARCH COORDINATOR Investigational New Drug Application-Sponsor Responsibilities 21CFR Part , subpart D

INVESTIGATIONAL PRODUCT ACCOUNTABILITY, STORAGE, DISPENSING, TRANSPORT AND RETURN

POST-IRB APPROVAL FDA DRUG (IND) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR312)

FDA Sponsor and Investigator Responsibility Checklist

Facilitating Compliance with 21 CFR Part 11

Study Files and Filing

1 The Clinical Research Coordinator (CRC)... 1

Standard Operating Procedures Guidelines for Good Clinical Practice

Annex IV to guidance for the conduct of good clinical practice inspections sponsor and CRO

Introduction to 21 CFR 11 - Good Electronic Records Management

PhlexEview: Transforming Costly Paper Processes into Value Driven Compliance

NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES

Investigator Site File Index (Medical Devices)

4. RELATED DOCUMENTS AND FORMS 4.1. AS ISO Cambridge Valley Machining, Inc. QMS procedures, including, but not limited to:

LOUGHBOROUGH UNIVERSITY RESEARCH OFFICE STANDARD OPERATING PROCEDURE. Loughborough University (LU) Research Office

ANCHOR ISO9001:2008 RPR-007 MARINE SERVICES ADDITIONAL PROCEDURE PRODUCT REALISATION

Responsible Conduct of Research Providing credible, reliable data (PREP Course #7)

Source Documents and Regulatory Binders October 6, 2016

CUSTOMER AND SUPPLIER ROLES AND RESPONSIBILITIES FOR 21 CFR 11 COMPLIANCE ASSESSMENT. 21 CFR Part 11 FAQ. (Frequently Asked Questions)

Audit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd.

11 Hidden Features of electronic Trial Master Files (etmfs) to Optimize the Value of Your etmf

Procedures at DF/HCC Transferring Site

Compliance and Quality Monitoring: What, Why, When, and How

Clinical Trial Performance Metrics

INVESTIGATIONAL DRUG MANAGEMENT OVERVIEW

Product Realization. Ameritube LLC 1000 N. Hwy 77, Hillsboro TX Revision Level: Procedure No. A

ESSENTIAL DOCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL

ALCOA AND DATA INTEGRITY: PASTAND FUTURE

STANDARD OPERATING PROCEDURE FOR RESEARCH. 17. Study Close Down

It s All About The RISK

High Quality or Poor Quality DB

Introduction to Clinical Research

STANDARD OPERATING PROCEDURE

Ensure Data Integrity Compliance Enterprise-Wide

Data Integrity Issues & Concerns PDA Meeting Kansas City, MO August 21, 2017

ZOLL Document Number: 90E0004 Page 5 of 15 Maintenance of Quality Records

Quality Manual ISO 9001:2008 ISO 9001:2015

STUDY REQUEST FORM AND TRAQ DSS FORM

A Comprehensive Approach to Find and Remediate Data Integrity Problems

Preparing for Close-Out of Studies and Sites

PHARMACY, MEDICINES & POISONS BOARD

Regulatory Document Guidelines for DMID Clinical Studies. Version Oct-2005

ORC Sponsor-Investigator IDE Checklist

Regulatory Binder Guidance

ISPE NORDIC COP CLEAN UTILITIES SEPTEMBER TUUSULA FINLAND. Timo Kuosmanen STERIS Finn-Aqua

ELEMENTS OF A DATA MONITORING PLAN

Louise Brook Clinical Trials Quality Monitor. Date

St. Luke s University Health Network

STANDARD OPERATING PROCEDURE

10/17/2016. Learning Objectives. What is Drug Accountability. Patricia Novo, MPA, MPH Beth Jeffries, BS, CCRP

Patricia Novo, MPA, MPH Beth Jeffries, BS, CCRP

3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.

Guidance for Industry Part 11, Electronic Records; Electronic Signatures Scope and Application

3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.

Implementing Good Clinical Practice at an Academic Research Institution

Use of computerised equipment, software and systems in clinical research

Demystifying Audits. Audits and Audit Preparation 5/23/2016. What is an Audit?

GxP Auditing, Remediation, and Staff Augmentation

Standard Operating Procedure

STANDARD OPERATING PROCEDURE. STH Researcher. Investigator Site File

ROLE OF THE RESEARCH COORDINATOR Study Startup Best Practices May 2016

Conducting and reporting a GCP Inspection. Gunnar Danielsson Medical Products Agency

Incorporating Risk- Based Monitoring Strategies: Challenges in Implementation Sherri Hubby, Director, U.S. Quality Assurance

Phlexglobal Whitepaper

11.0 FDA-Regulated Research Research Involving Investigational Drugs and Biologics

Index of Standard Operating Procedures for all research Sponsored by the UHL

Sponsor/Investigator Responsibilities

and Study Initiation

and Study Initiation

Reducing the Time to Market with an eclinical System

GxP Auditing, Remediation, and Staff Augmentation

Trial Services. The allround trial specialist in cardiology Leading since cardialysis.com

11.0 FDA-Regulated Research Research Involving Investigational Drugs and Biologics

ISO 9001:2015 Internal Audit Checklist 7.0 Support

GCP Basics - refresher

GxP Auditing, Remediation, and Quality System Resourcing

Index of Standard Operating Procedures for all research Sponsored by the UHL

Source And Regulatory Documentation for DMID Clinical Studies

Human Research Protection Program Good Clinical Practice Guidance for Investigators Regulatory File Essential Documents

Topics summarised in this presentation are: method for defining quality level you want meaning of external controls quality assurance activities

Hong Kong Deposit Protection Board

Clinical Trial Basics:

Investigator Site File Index (CTIMP)

Could Poor Temperature Data Management be Putting Your GxP Facility at Risk for Data Integrity Violations? we prove it.

New Data Integrity Regulations and Practical Advice for Life Science Laboratories. we prove it.

Revision. Quality Manual. Multilayer Prototypes. Compliant to ISO / AS9100 Rev C

IT Compliance in the FDA Regulated Industry. IT Responsibilities 10 Years Ago TODAY! 11/17/2008. Business. Security. Compliance. IT & Automation Forum

11.0 FDA-Regulated Research

OFFICE FOR RESEACH PROCEDURE. Site Initiation and Close-out

Standard Operating Procedures (SOP) Research and Development Office

Transcription:

The pocket guide to ARCHIVING REGULATIONS How to Maintain Compliance & Drive Efficiencies at Study Closeout

Pocket Guide Pocket Guide to Archiving Regulations Being able to easily manage the site archive process and the TMF protects your company from significant content and regulatory risk. However, there are often significant hurdles to overcome in order to achieve 100% compliance and be completely prepared for an audit. In this pocket guide, we ll dissect the critical regulations that impact your compliance and identify the most common challenges to achieving it. We ll also provide tips for driving efficiencies during your study closeout process. Important Regulations Dissected Guidance for Industry Scope and Application, August 2003 Copies of Records: The agency intends to exercise enforcement discretion with regard to specific part 11 requirements for generating copies of records. You should be prepared to provide an investigator with reasonable and useful access to records during an inspection. You will want to have the capability to do so in a timely manner in order to avoid wasted time in searching for records. We recommend that you supply copies of electronic records by producing copies of records held in common portable formats and by using established automated conversion methods, where available, to make copies in a more common format. In each case, we recommend that the copying process used produce copies that preserve the content and meaning of the record. If you have the ability to search, sort, or trend part 11 records, copies given to the Agency should provide the same capability if it is reasonable and technically feasible. You should allow inspection, review, and copying of records in a human readable form at your site using your hardware. Guidance for Industry Computerized Systems Used in Clinical Trials, 1999 FDA may inspect all records that are intended to support submissions to the Agency, regardless of how they were created or maintained. Therefore, systems should be able to generate accurate and complete copies of records in both human readable and electronic form suitable for inspection, review, and copying by the Agency. Persons should contact the Agency if there is any doubt about what file formats and media the Agency can ready and copy.

Interpretation of Regulatory Requirements by Technology Providers The Case for Electronic Source Data, 2002 Taken together, the regulations and guidance bearing on electronic records and e-sources in clinical trials concern data integrity. Both the Rule on Electronic Records and Signatures and Guidance for Industry: Computer Systems Used in Clinical Trials emphasize the agency s intent to set forth the steps needed for computer systems to ensure that the pedigree of the data with electronic records would be as trustworthy as with paper records. The predicate rules spell out that data and record integrity are important and that case history data, including source data and CRFs, are to be prepared, maintained, and retained by the investigator. A system compliant with 21 CFR Part 11 that is designed to provide the sites with ready access and the capability to enter, edit, review, authenticate, and maintain all of their electronic records for a clinical trial might well meet the regulatory requirements and guidance currently issued. To fulfill the criteria for data quality mentioned in the Guidance, such a system should ensure that electronic records are attributable, legible, contemporaneous, original, and accurate (ALCOA) and that they are protected in such a way as to enable their accurate and ready retrieval throughout the record retention period. In addition to what the regulations do say, consider what they don t say. Many of the terms used in Dr. Bleicher s column, including the phrases controlled certified copy, investigator controlled data, physical ownership and control, local control, local copy, local archival control, and archival control of data do not appear anywhere in the regulations. Only the terms prepare, maintain, and retain appear in the regulations. Precedents with paper records that fulfill the records retention requirement include the storage of the records in a central facility (on- or off-site) and the use of contractors, such as Iron Mountain, to store records in secure warehouses. Laboratory data is often held offsite in computerized systems that are under contract to the sponsor. Regulations indicate that the site should have ready access to such data and, specifically, that FDA inspectors should have access to such data for purposes of review at the site. But nowhere does it appear that the only satisfactory solution to meeting such requirements is for the site to physically possess local hardware on which its electronic records are stored.

Journal of Clinical Research Best Practices Study Closeout at Research Sites, 2009 Complete the following activities to close out a study: Follow-up on serious adverse events (SAEs) and clinically significant, abnormal lab values and clinical observations for at least thirty days after the subject completes the study. If not resolved at the end of the period, document in the source documents and notify the sponsor. Lineout, initial and date any empty comment fields in source documents. Complete all case report forms (CRFs) and transmit them to the sponsor. Respond to all open requests for data corrections or verifications on CRFs. Document unresolvable queries. After all data queries have been resolved, check study files for completeness. Collect all study drug and equipment from study subjects. Inventory all used and unused study drug. Reconcile or explain discrepancies, if any. Inventory any stored lab specimens and determine their disposition. Inventory all sponsor-provided equipment and determine its disposition. Return drugs, empty containers, supplies, devices and equipment to the sponsor per its instructions, unless instructed to retain or destroy them by the sponsor. Include packing slips with shipments. Retain copies of shipping documentation. File copies of drug logs, final inventory, and shipping documents in the regulatory binder. File a copy of the sponsor s drug disposal authorization, if any, in the regulatory binder.

If the randomization code on any study drug was broken for any reason, ensure that complete documentation is in the regulatory binder. Obtain updated financial disclosure forms from the investigator and any sub-investigators. Complete all other sponsor-required reports in a timely manner. File copies in the regulatory binder Review the regulatory binder. Ensure that all documents are in their correct places. Complete incomplete documents and recover any missing documents, or place an explanatory note-to-file in the regulatory binder. On the subject completion form and in medical charts, document subject completion of the subjects participation in the study. Remove from the subjects medical charts any medication restrictions or study warnings, if applicable. Complete the IRB annual renewal form indicating final or closure and submit the report. Include a short narrative summary of the conclusion of the study at the site. Include comments on any adverse events (AEs) that occurred and the significance they may have had on study findings. Provide a copy of the report to the sponsor and file it in the regulatory binder. For each subject, the principal investigator signs an investigator statement confirming that all data for that subject are complete and accurate. Take down any subject recruiting posters and website postings. Notify sub-investigators, pharmacy, clinical lab, accounting office, and other departments that the study has been completed, with appropriate closeout instructions. Conduct study closeout visit. Package all study documentation for storage. Include an inventory statement. Archive all study documentation in a secure location, ensuring that it will be stored for the period of time specified in the clinical trial agreement.

Common Challenges of Compliance Even with a complete understanding of the pertinent regulations, compliance is no walk in the park. Here are some common challenges to achieving compliance and preparing your site for an audit. Administrative Requirements Certain administrative and project management tasks can put a significant strain on a team. Site personnel often find themselves devoting a lot of time to fulfilling these duties when they should be focusing on the more critical elements to the study. Timeframes It takes an average of 12 years for a drug to travel from the laboratory to your medicine cabinet. Sites are being forced to do more with less time. Delays on the front end of trials often put pressure on sites to move quickly through study closeout and archiving processes. As is true with any project, moving quickly often leads to costly mistakes and oversights. Budgets As studies become more complex and expensive, budgets are increasingly allocated elsewhere, leaving the study closeout processes to make do. Shortcuts can be made in order to work within a given budget, but that can derail your study close and archiving results, putting you at significant risk in the case of an audit.

5 Ways to Drive Efficiencies Despite the challenges facing study closeout teams, there are certain tactics that your site can implement to help overcome hurdles and get your study closed out on time, within budget, and with as little strain on your team as possible. Here are a few tips to get you started: Simplify the Process The first step to driving efficiencies in any process is to take a good look and understand it from the ground up. Take a proactive approach to understand where the redundancies and loopholes exist, and resolve them. Make every piece of the process as simple and seamless as possible. Validated System Work with a vendor who can offer you a proven and validated system. Rest easy knowing that the vendor has gone through the hurdles required to deliver a trusted and effective solution to your team. Cloud-Based/Global Access Providing cloud-based, 24/7 access to team members around the globe allows you to minimize the impact of time zone and location differences, as well as communication barriers. Allow your team members around the world to access the information they need in a timely manner. Secure/Long-Term Data Invest in secure systems that encrypt or password-protect your files, and maintain your archives for 100+ years. Breathe easy knowing your files are safe and accessible. Outsource Project Management Hand off certain administrative tasks to the experts and free up your personnel for more study-critical activities, allowing them to close sites quicker. Partner with an organization who can provide electronic documentation and systematic communication with sites to expedite your administrative processes.

Want to learn more? Download our brochure any time! DOWNLOAD NOW We d love to hear from you! www.impgraphics.com 855.818.3406 materials@impgraphics.com